Cargando…
In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts
Epidermal growth factor receptor (EGFR), upregulated in gastric cancer patients, is an oncogene of interest in the development of targeted cancer nanomedicines. This study demonstrates in silico modeling of monoclonal antibody cetuximab (CET MAb)-conjugated docetaxel (DOCT)-loaded poly(γ-glutamic ac...
Autores principales: | Sreeranganathan, Maya, Uthaman, Saji, Sarmento, Bruno, Mohan, Chethampadi Gopi, Park, In-Kyu, Jayakumar, Rangasamy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628680/ https://www.ncbi.nlm.nih.gov/pubmed/29033568 http://dx.doi.org/10.2147/IJN.S143529 |
Ejemplares similares
-
In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]
Publicado: (2019) -
Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II
por: Zhang, Keqiang, et al.
Publicado: (2020) -
Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy (†)
por: Sihver, Wiebke, et al.
Publicado: (2014) -
Design of theranostic nanomedicine (II): synthesis and physicochemical properties of a biocompatible polyphosphazene–docetaxel conjugate
por: Jun, Yong Joo, et al.
Publicado: (2017) -
A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
por: Zhang, Lianhai, et al.
Publicado: (2013)